Supporting caregivers in transitioning children to pDTG

Events

Supporting caregivers in transitioning children to pDTG

In this edition of the Evidence to Action (E2A) webinar, The U.S. President's Emergency Plan for AIDS Relief (PEPFAR), the U.S. Agency for International Development (USAID), Caris Foundation International, and the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) will discuss practical ways that communities and caregivers can support children living with HIV in their transition to pediatric dolutegravir (pDTG). This webinar builds on the momentum around WHO’s guidance recommending dolutegravir as the preferred anchor ARV for people living with HIV and the recent availability of pDTG to treat children down to 4 weeks of age and who weigh at least 3 kilograms. This discussion will include a review of new science, to be published at the 2021 International AIDS Society Conference. OVC programs and community organizations supporting families with children who receive HIV treatment, including Pact, will share their experiences promoting demand creation, reinforcing treatment literacy, and offering ART adherence support to caregivers of children transitioning to a new ARV.

  • Opening Remarks, Chip Lyons EGPAF-global 
  • Catching up on the science: Summary of pDTG evidence from IAS 2021, Dr. Lynne Mofenson, EGPAF-global
  • A caregiver experience in transitioning a child to pDTG, Dr. Nathaniel Segaren, Caris Foundation International
  • The multiple and overlapping roles of OVC programs and CSOs in supporting countries to transition to new pediatric ARVs, Dr. George Siberry, USAID Office of HIV/AIDS
  • OVC program’s support to caregivers of children transitioning to new pediatric ARVs, Asheri Barankena, Pact
  • CSOs supporting caregivers to transition to new pediatric ARVs, Florence Anam from GNP+ 
  • Moderated discussion, Dr. George Siberry
  • Closing remarks, USAID Office of HIV/AIDS